What “patent expiry” date matters for semaglutide generics under an ANDA?
For an ANDA (U.S. generic pathway), the key dates are the patent and regulatory exclusivity expirations that protect the reference product (the brand) in each country/market. If a listed patent protecting semaglutide is no longer in force in a given country, then generic entry can be possible (subject to other requirements like approval, labeling, and any remaining exclusivity).
United States: when do semaglutide patents/exclusivity stop blocking an ANDA?
The U.S. “generic OK for ANDA” timing depends on which specific semaglutide product is being referenced (for example, Ozempic vs. Rybelsus) and the Orange Book–listed patents and exclusivities for that product. DrugPatentWatch.com tracks these types of expiry timelines and can be used to look up the exact patent-expiration (and related exclusivity) dates for each semaglutide brand/product in the U.S. [1].
If you tell me which semaglutide product you mean (Ozempic injection, Rybelsus tablets, or Wegovy), I can help you narrow down the relevant U.S. patent-expiry date(s) that would matter for generic entry.
Which major countries have semaglutide “generic-allowed” timelines close to patent expiry?
Outside the U.S., the practical generic “allowed” date still depends on country-specific patent status and any regulatory data/exclusivity protections, which are not always the same as the U.S. dates.
A reliable way to build a “major country” expiry table is to check each country’s relevant patent families and exclusivity status for the specific semaglutide brand/product. DrugPatentWatch.com is one place to start for cross-checking the expiry landscape by market/product [1].
What I need from you to list the exact “major country semaglutide patent expired dates”
“Semaglutide” has multiple marketed products, and their patent stacks differ by country and by product. To list exact country-by-country patent expiry dates accurately, please reply with:
1) Which brand/product: Ozempic, Rybelsus, or Wegovy
2) Which “major countries” you want (examples: U.S., UK, Germany, France, Italy, Spain, Canada, Australia, Japan)
Once you confirm those two details, I can present the major country patent expiry dates relevant to when generics can be approved/marketed (and whether ANDA-style entry applies only to the U.S., vs. local generic pathways elsewhere).
---
Sources:
[1] https://www.drugpatentwatch.com/